ArticlePediatric rheumatology online journal2026
Serum bile salt-stimulated lipase levels associates with systemic inflammation and declines with effect of treatment in juvenile idiopathic arthritis.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJuvenile idiopathic arthritis (JIA) is among the most common autoimmune diseases in children, yet its pathophysiology remains incompletely understood. Reliable biomarkers are needed to assess disease activity and guide therapy. Bile salt-stimulated lipase (BSSL), originally identified as a lipolytic enzyme, has recently been implicated in inflammatory conditions such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in adults. Elevated serum BSSL levels correlate with markers of inflammation and decrease following positive response to anti-inflammatory treatments, suggesting potential utility as both a biomarker and a therapeutic target.
methodsSerum BSSL concentrations were measured in children with JIA and compared with healthy controls. Correlations between BSSL and inflammatory markers (S100A8/A9, HNL), blood cell counts (leukocytes, neutrophils, platelets), and clinical disease-activity indices (ESR, JADAS27, cJADAS27, CHAQ) were evaluated.
resultsChildren with JIA had significantly higher serum BSSL concentrations than healthy controls, and levels decreased following medical treatment. BSSL correlated positively with platelets, ESR, and S100A8/A9, but not with JADAS27.
conclusionSerum BSSL tracks systemic inflammatory activity and decreases with clinical improvement in JIA, supporting its further evaluation as a complementary inflammatory biomarker and potential pharmacodynamic read out in pediatric inflammatory arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.